InVivoMAb anti-mouse CTLA-4 (CD152)

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Ariyan CE et al., 2018 Feb, Cancer Immunol Res

Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Gao J et al., 2016 Oct 6, Cell

Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Bartkowiak T et al., 2015 Sep 22, Proc Natl Acad Sci U S A

Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Spranger S et al., 2015 Jul 9, Nature

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Twyman-Saint Victor C et al., 2015 Apr 16, Nature

Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Stephan SB et al., 2015 Jan, Nat Biotechnol

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Oezdemir BC et al., 2014 Jun 16, Cancer Cell

Candida-elicited murine Th17 cells express high Ctla-4 compared with Th1 cells and are resistant to costimulation blockade. Krummey SM et al., 2014 Mar 1, J Immunol

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. Goding SR et al., 2013 May 1, J Immunol

Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. Hervieu A et al., 2013 Feb, J Invest Dermatol